BridgeBio Pharma Inc (NASDAQ:BBIO)
| 16.61 Delayed Data As of Mar 31 |  -0.54 / -3.15%Today’s Change | 4.98 Today|||52-Week Range 19.95 | +117.98% Year-to-Date |
Latest BBIO News | Press Releases
| BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last? Mar 27 / Zacks.com - Paid Partner Content | BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why Mar 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 17.15 |
| Today’s open | 17.23 |
| Day’s range | 16.41 - 17.80 |
| Volume | 127,621 |
| Average volume (3 months) | 2,483,006 |
| Market cap | $2.3B |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +16.27% |
| Earnings growth (this year) | +8.98% |
| Earnings growth (next 5 years) | -51.17% |
| Revenue growth (last year) | +11.38% |
| P/E ratio | NM |
| Price/Sales | 14.47 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IDRSFIdorsia Ltd | -0.30 | -2.64% |
| OASMYVivesto AB | 0.00 | 0.00% |
| ---- | ||
| IMMBImmunotech Laborator... | 0.00 | 0.00% |
Data as of 03/28/2023
Financials
| Next reporting date | May 4, 2023 |
| EPS forecast (this quarter) | -$0.82 |
| Annual revenue (last year) | $77.6M |
| Annual profit (last year) | -$481.2M |
| Net profit margin | -619.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Palo Alto, California |
Forecasts
